A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Launched by MERCK SHARP & DOHME LLC · May 13, 2025

Keywords

ClinConnect Summary

This clinical trial, called MK-5684-015 or OMAHA-015, is studying a new medicine named MK-5684 to see if it can help treat certain types of cancer, specifically breast, ovarian, and endometrial cancer. The researchers want to find out if patients taking MK-5684 can live longer without their cancer growing or spreading compared to those receiving standard treatments. This trial is currently not recruiting participants.

To be eligible for the study, participants must have specific types of cancer: for breast cancer, they should have a certain type that has already progressed after prior treatment; for ovarian cancer, they should have received a specific number of chemotherapy cycles; and for endometrial cancer, they should have a confirmed diagnosis that meets certain criteria. The study is open to all genders and focuses on patients aged 65-74. Participants can expect to receive either MK-5684 or standard treatment and will be monitored for their health and response to the medication throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The main inclusion criteria include but are not limited to the following:
• * Cohort A:
• • Has a diagnosis of hormone receptor positive/Human Epidermal Growth Factor Receptor 2 negative (HR+/HER2-) invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or metastatic disease not treatable with curative intent.
• • Has experienced disease progression on or after at least 1 prior endocrine-based therapy in the metastatic setting.
• * Cohort B:
• • Has histologically confirmed high-grade epithelial (including high-grade serous or predominantly serous, high-grade endometrioid, malignant mixed Müllerian tumors \[carcinosarcoma\], or clear cell) ovarian, fallopian tube, or primary peritoneal carcinoma.
• • Has received between 4 to 8 cycles of platinum-based doublet chemotherapy in third-line (3L) setting for ovarian cancer.
• * Cohort C:
• • Histologically confirmed diagnosis of primary advanced or recurrent low-grade endometrioid carcinoma (eg, Federation of Gynecology and Obstetrics \[FIGO\] Grade 1/2, or well/moderately differentiated).
• • Treatment naïve or has received up to 1 prior line of platinum-based therapy in either the advanced/metastatic OR adjuvant/neoadjuvant setting.
• * All Cohorts :
• • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline.
• • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
• • Participants who are Hepatitis B surface antigen positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load.
• • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
• Exclusion Criteria:
• The main exclusion criteria include but are not limited to the following:
• * Cohort A:
• • Breast cancer amenable to treatment with curative intent.
• • Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications, such as lymphangitic lung metastases, radiographic evidence of intratumoral cavitation or invasion/infiltration of a major blood vessel, bone marrow replacement, carcinomatous meningitis, significant symptomatic liver metastases, symptomatic pericardial effusion, symptomatic peritoneal carcinomatosis, or the need to achieve rapid symptom control.
• * Cohort B:
• • Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, low-grade serous, low-grade endometrioid, and undifferentiated carcinoma.
• • Has platinum-resistant ovarian cancer (defined as disease that has progressed per radiographic imaging within 180 days after the last dose of first-line \[1L\] platinum-based therapy) or platinum-refractory ovarian cancer (defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of 1L platinum based therapy).
• • Is a candidate for curative-intent surgery or curative-intent radiotherapy for ovarian cancer.
• * Cohort C:
• • Has high-grade (FIGO Grade 3 or poorly differentiated) endometroid carcinoma and nonendometrioid histologies of any type (including serous, clear cell, mixed, carcinosarcoma), and neuroendocrine tumors are not eligible. Uterine mesenchymal tumors such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas, and adenosarcomas are not eligible.
• • Is a candidate for curative-intent surgery or curative-intent radiotherapy.
• * All Cohorts:
• • Has confirmed or suspected adrenal metastases.
• • Has known difficulty in tolerating oral medications, unable to swallow orally administered medication, or conditions which would impair absorption of oral medications.
• • Has any prior history or current condition of adrenal insufficiency.
• • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
• • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
• • Has known active central nervous system metastases and/or carcinomatous meningitis.
• • Has a history of stem cell/solid organ transplant.
• • Has not adequately recovered from major surgery or has ongoing surgical complications.